ALI HEALTH, the healthcare subsidiary of Alibaba Group, witnessed a significant surge of 8.33% in its stock price on Friday, riding on the back of robust earnings and the company's substantial progress in its "user first, AI-driven" strategies.
The company reported a revenue of 280.15 billion yuan ($38.38 billion) for the period, marking an 8% increase from the previous year and aligning closely with analysts' expectations of 279.34 billion yuan. The strong financial performance was underpinned by the company's strategic focus on leveraging artificial intelligence to enhance user experience.
ALI HEALTH's positive performance was further buoyed by the broader rally in Alibaba-linked stocks. Yunfeng Fin, another Alibaba affiliate, soared an impressive 13%, while the parent company Alibaba itself saw its shares soar by 10%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。